Bromodeoxyuridine hypersensitivity of metastatic melanoma cells
| Autor: | Otto F, H. Hoehn, M. Poot, Ulrich Bogdahn |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Cancer Research
medicine.medical_treatment Dermatology Flow cytometry chemistry.chemical_compound medicine Humans Melanoma Lymph node Chemotherapy Dose-Response Relationship Drug medicine.diagnostic_test Brain Neoplasms Cell Cycle Cell cycle Flow Cytometry medicine.disease Molecular biology Oxygen medicine.anatomical_structure Bromodeoxyuridine Oncology chemistry Cell culture Lymphatic Metastasis Lymph Nodes Drug Screening Assays Antitumor Growth inhibition |
| Zdroj: | Melanoma Research. 2:241-246 |
| ISSN: | 0960-8931 |
| Popis: | A model system for testing the efficacy of chemotherapy protocols for metastatic melanoma was established using cell cultures from two brain and three lymph node metastases of melanoma from five different patients. Continuously growing cultures which were positive for tyrosinase activity were analysed regarding their proliferation rate by continuous bromodeoxyuridine (BrdU) labelling and subsequent Hoechst-33258/ethidium bromide flow cytometry. Melanoma cell cultures exhibit a strong sensitivity to BrdU: at 5% oxygen, 50% growth inhibition is attained with 360 +/- 130 microM BrdU (range: 130-520; n = 11) vs 650 +/- 50 microM BrdU (n = 3) for diploid human fibroblasts and 570 +/- 20 microM BrdU (n = 6) for human lymphoid cell lines. Moreover, BrdU sensitivity of melanoma cells is clearly oxygen dependent: 50% growth inhibition at 200 +/- 55 microM (range: 65-400 microM) for 20% oxygen vs 360 +/- 130 microM BrdU for 5% oxygen. The cell cycle kinetic mechanism of BrdU-induced growth inhibition is accumulation of cells in the first cycle G2 phase. On the basis of these results we suggest testing BrdU in chemotherapy protocols for the treatment of metastatic melanoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|